Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pregabalin In Adolescent Patients With Fibromyalgia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01020526
First received: November 23, 2009
Last updated: May 24, 2016
Last verified: May 2016

November 23, 2009
May 24, 2016
September 2010
June 2015   (final data collection date for primary outcome measure)
Change From Baseline in Pain Numeric Rating Scale by Week [ Time Frame: Baseline, Weeks 3, 8, 16, 24 and Last Visit. ] [ Designated as safety issue: No ]
The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain. Participants chose the number that best described the pain during the last week. Negative change indicates improvement.
Primary Efficacy Endpoint- Pain Numeric Rating Scale (NRS) [ Time Frame: 6 month ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01020526 on ClinicalTrials.gov Archive Site
Not Provided
There are no secondary endpoints [ Time Frame: There are no secondary endpoints ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Pregabalin In Adolescent Patients With Fibromyalgia
A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia
The main purpose of this study is to evaluate the long-term safety of pregabalin in adolescent patients who participated in the previous fibromyalgia study (A0081180) and who wish to recieve open-label pregabalin
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Masking: Open Label
Primary Purpose: Treatment
Fibromyalgia
Drug: pregabalin
Oral capsule 75-450 mg/day
Experimental: Pregabalin
Intervention: Drug: pregabalin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
63
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have met the inclusion criteria for the preceding fibromyalgia Study A0081180, and have received pregabalin/placebo under double-blind conditions.

Exclusion Criteria:

  • Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia study A0081180 which was determined to be related to the study medication by the investigator or sponsor.
Both
12 Years to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Czech Republic,   India
Taiwan
 
NCT01020526
A0081231, 2010-020300-29
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP